Abstract:ID 90930 Poster Board 516 Text Parkinson's disease (PD) is a prevalent neurodegenerative condition characterized by degeneration of dopaminergic neurons in the substantia nigra of the midbrain. This results in bradykinesia, tremors, rigidity, and other motor and non-motor deficits. The prevalence of PD is increasing, in part, due to the aging population. Despite this growing burden, the development of effective therapies to halt disease progression remains an unmet need. This challenge is due to gaps in our understanding of the molecular mechanisms underlying the disease and deficiencies of preclinical models in recapitulating all aspects of the pathobiology of PD. Consequently, deepening our understanding of pathobiology and discovering druggable targets remain a research priority. Herein, we describe assay development and optimization of a high throughput phenotypic screen in the roundworm Caenorhabditis elegans for discovery of novel druggable targets and genetic influencers of neurodegeneration and neuroprotection. We utilized two transgenic C. elegans strains expressing human PD-linked genes—one with mutant (A53T) alpha-synuclein (SNCA) and the other expressing mutant (G2019S) leucine-rich repeat kinase 2 (LRRK2). These strains exclusively express the PD-related transgenes and green fluorescent protein (GFP) in their dopaminergic neurons, facilitating the tracking of neurodegeneration through measurable changes in the GFP fluorescence. Using laser cytometry and high content imaging with worms growing in liquid culture within 384-well plates, we assessed the health of the dopamine neurons via GFP intensity, number of neurons, and area of green objects. We observed a 30-50% and 75-85% decrease in GFP intensity in the SNCA and LRRK2 worms, respectively, by day seven compared to wild-type controls lacking the PD genes but expressing GFP exclusively in the dopaminergic neurons. We crossed the worms to RNAi hypersensitive backgrounds carrying eri-1, rrf-3, and eri-1;lin-15B mutations to overcome the typical resistance to neuronal RNAi knockdown in C. elegans . We observed a robust RNAi knockdown in the control and mutant worms with a 50-75% knockdown on day seven with RNAi against GFP, ama-1, ceh-43, and unc-62 compared to empty vector control. RNAi specifically engineered against the LRRK2 transgene slows neurodegeneration in the LRRK2 mutant worms. Additionally, we have identified selective LRRK2 kinase inhibitors that confer neuroprotection in the LRRK2-carrying worms with promising properties to serve as controls for high throughput molecular library screening. Further optimization studies are ongoing with the goal of conducting a screen for genes influencing neuroprotection in these models. Additionally, we plan to conduct a small molecule library screen for novel neuroprotective compounds using these PD models. These lines of inquiry may identify new molecules or potential druggable targets for novel therapeutics for influencing neurodegeneration and PD progression. Supported by the NINDS Intramural Research Program.

Caenorhabditis Elegans As a Model System for Target Identification and Drug Screening Against Neurodegenerative Diseases.

Modeling neurodegeneration in Caenorhabditis elegans

Genetic and Pharmacological Discovery for Alzheimer's Disease Using Caenorhabditis elegans.

A Brief Review on Caenorhabditis elegans Role in Modelling Neurodegenerative Disease

Modelling Parkinson's Disease in C. Elegans: Strengths and Limitations

C. elegans: a prominent platform for modeling and drug screening in neurological disorders

Identification of Small-Molecule Ion Channel Modulators in C. Elegans Channelopathy Models.

Caenorhabditis elegans: A Convenient In Vivo Model for Assessing the Impact of Food Bioactive Compounds on Obesity, Aging, and Alzheimer's Disease

The contribution of C. elegans neurogenetics to understanding neurodegenerative diseases

Simple models to understand complex disease: 10 years of progress from Caenorhabditis elegans models of amyotrophic lateral sclerosis and frontotemporal lobar degeneration

Amyotrophic Lateral Sclerosis Mechanism: Insights from the Caenorhabditis elegans Models

A living model for obesity and aging research: Caenorhabditis elegans

Finding Function in Novel Targets: C. Elegans As a Model Organism.

Caenorhabditis Elegans As a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity.

Using Caenorhabditis elegans to Model Therapeutic Interventions of Neurodegenerative Diseases Targeting Microbe-Host Interactions

Model organism C.elegans applications in the complex-system drug activity evaluation

Research and application progress of Alzheimer’ s disease model on Caenorhabditis elegans

Caenorhabditis elegans in Chinese medicinal studies: making the case for aging and neurodegeneration.

Caenorhabditis elegans as a Useful Model for Studying Aging Mutations

Neuroprotection in C. Elegans Parkinsons Disease Models: Discovering Therapeutic Insights via RNAi and Small Molecule High Throughput Screening

Exploring Caenorhabditis elegans as Parkinson's Disease Model: Neurotoxins and Genetic Implications